Your Site Title

PatchClamp MedTech, Inc.

PatchClamp Medtech, Inc. (PMI) is a Delaware C Corp located in Seattle WA. Dr. Marc Mayberg has invented a patent-protected medical device that addresses a large unmet need in minimally-invasive surgery (MIS) of the brain and spine. Seattle-based engineering firm Product Creation Studio www.productcreationstudio.com has created the prototype for a minimally invasive device that will repair and seal MIS incisions of the dura, reducing the risk of infection, improving the speed of closure and accelerating healing after complex neurosurgical procedures. To assist in the perfection of its prototype, PatchClamp has received a $500,000 phase one grant from the NIH.

PatchClamp MedTech, Inc. is a medical device company located in Seattle, WA. The device REPAIRs AND SEALs THE DURA IN MINIMALLY INVASIVE SURGICAL PROCEDURES.

Purpose

We intend to develop an FDA approved, affordable and reliable technology for repairing and sealing dural openings (incisions or punctures) in MIS procedures.

Impact

PMI will achieve Better Outcomes at a Lower Cost by properly repairing and sealing the dura in restricted surgical exposures. The device will; reduce complications, improve outcomes, lower hospital costs, decrease hospital readmissions, and shorten OR time.

PRODUCT DESCRIPTION

40 years of Dr. Mayberg’s experience as a Neurosurgeon encompassing more than 3,000 operations has led to the conception of the MedTech device, PatchClamp, to quickly and effectively repair and provide an immediate watertight seal for openings of the dura encountered in MIS and open surgical procedures. Repair and sealing of the dura that surrounds the brain and spine is critical to prevent leakage of cerebrospinal fluid, which frequently leads to serious complications such as meningitis.

IP DESCRIPTION

Dr. Mayberg and Product Creation Studios have assigned all base IP to PMI resulting from dural repair inventions. PMI has filed and received a patent detailing the PatchClamp tissue sealing device as of January, 2020. A USPTO utility patent and simultaneous Prioritized Patent Examination has been approved as of January, 2021. PMI in 2022 applied for international patents.